An elderly male went for a medical examination. Laboratory investigations showed a marked elevation of lymphocytes with marked leukocytosis. The peripheral smear of the patient is given below. What is the appropriate next step for this patient?

Correct Answer: B. Flow cytometry

In a patient presenting with marked leukocytosis and lymphocytosis on peripheral smear, the critical discriminating step is immunophenotyping via flow cytometry. This is the appropriate next diagnostic step because it definitively classifies the lymphoproliferative disorder—distinguishing between reactive lymphocytosis (infection, inflammation) and clonal malignancies (chronic lymphocytic leukemia, acute lymphoblastic leukemia, lymphoma). Flow cytometry identifies abnormal CD antigen expression patterns (e.g., CD5+/CD19+/CD23+ in CLL, or aberrant CD10/CD19 in ALL), which guides prognosis and treatment strategy. In Indian clinical practice, this is the standard second-line investigation after peripheral smear morphology in any patient with unexplained lymphocytosis. The test is rapid, cost-effective, and provides definitive immunological classification essential before committing to stem cell transplantation or chemotherapy. Without flow cytometry data, initiating aggressive therapy would be premature and potentially harmful if the lymphocytosis is reactive.

Why the other options are wrong

A. Stem cell transplantation — Stem cell transplantation is a definitive therapeutic intervention reserved for advanced or high-risk hematologic malignancies after complete diagnostic workup and risk stratification. Performing it as the next step without immunophenotyping, cytogenetics, and disease staging would be premature and potentially futile. This is a treatment endpoint, not a diagnostic step. C. Bone marrow biopsy — While bone marrow biopsy is valuable for assessing marrow cellularity and morphology in lymphoproliferative disorders, it is typically performed after flow cytometry to confirm clonality and guide further staging. Flow cytometry on peripheral blood is less invasive, faster, and provides the immunological classification needed to decide whether bone marrow examination is even necessary. D. Start high-dose chemotherapy — Initiating chemotherapy without definitive diagnosis and risk stratification violates standard oncology practice. The lymphocytosis could be reactive (viral infection, tuberculosis—common in India) or a low-grade malignancy. Flow cytometry must first confirm clonality and immunophenotype to select appropriate chemotherapy regimens and avoid unnecessary toxicity.

High-Yield Facts

Mnemonics

FLOW First in Lympho Flow cytometry → Lymphoproliferative diagnosis → Other tests (marrow, cytogenetics) → Work-up complete. Use when you see unexplained lymphocytosis on smear. Diagnostic Ladder in Leukocytosis Smear → Flow → Marrow → Cytogenetics → Treatment. Flow cytometry is the second rung; never skip to treatment (top rung) without it.

NBE Trap

NBE pairs "marked leukocytosis + elderly male" with stem cell transplantation or chemotherapy to trap students who confuse diagnostic steps with therapeutic endpoints. The question tests whether candidates understand that immunophenotyping must precede definitive treatment in any new lymphoproliferative presentation.

Clinical Pearl

In Indian practice, tuberculosis and viral infections (dengue, EBV) commonly cause reactive lymphocytosis in elderly patients; flow cytometry rapidly excludes malignancy and prevents unnecessary chemotherapy toxicity in these patients, many of whom have comorbid malnutrition and organ dysfunction.

_Reference: Robbins & Cotran Pathologic Basis of Disease, Ch. 13 (Hematopoietic and Lymphoid Systems); Harrison's Principles of Internal Medicine, Ch. 110 (Malignancies of Lymphoid Cells)_